Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
FAIL · Does not pass the screen
1.86 USD
Price as of 21 Sep 2026Daily close, not a live quoteLast reviewed 46 days ago
Screened 2026-09-21 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price1.86 USD at the 21 Sep 2026 close
Fair valueUnder review: its inputs are 35 days old; the analyst targets sit too far from the price to cross-check it.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.88, read 2026-10-27
Ethical does not pass the values gate
Price1.86 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Distribution1.86+0.0% to today Markdown gives way to Distribution
2026-10-02Read Markdown1.86+0.0% to today Markup gives way to Markdown after an 80% slide in 4 weeks
2026-09-03Read Markup9.51-80.4% to today Distribution gives way to Markup while volume is distributing
2026-08-04Read Distribution9.51-80.4% to today ✓Markdown gives way to Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Karyopharm Therapeutics Inc holds its Distribution at $1.86. The statistical read favours the sellers, held for 24 days.
As held on the ledger · 2026-09-21
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 24 days
Price at the screen
$1.86
Valuation
N/A trailing · -1.94 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.81
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
215.47%
Below 33%
Interest-bearing debt is 215.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.96%
Below 33%
Cash held in interest-bearing accounts and securities is 3.0% of assets, under the one-third limit.
Pass
Receivables
79.99%
Below 49%
Money owed to the company is 80.0% of assets, above the 49% limit.
Fail
Revenue purity
1.90%
Below 5%
Only 1.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Karyopharm Therapeutics's business is in a permissible area, but its interest-bearing debt is about 215% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KPTI's ethical verdict changes
Today KPTI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 35 days old; the analyst targets sit too far from the price to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KPTI trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-06Distribution$1.86+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-10-30Distribution$1.86+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-10-23Distribution$1.86+0.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-10-11Distribution · changed$1.86+0.0%Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-10-02Markdown · changed$1.86-80.4%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 80.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-09-03Markup · changed$9.51+0.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-08-04Distribution · changed$9.51+0.1%Entry 4
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-07-18Markdown$9.50+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 27% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it buy, with a mean price target of $14.
2026-07-03Markdown$9.50+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$9.50Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.